$GWAV

Greenwave Announces Receipt of Additional Delinquency Notice from Nasdaq

Greenwave Technology Solutions said Nasdaq issued an additional delinquency notice on May 21, 2026 for its delayed Q1 2026 Form 10-Q filing, citing noncompliance with Nasdaq Listing Rule 5250(c)(1). The company previously received a delinquency notice for its late 2025 Form 10-K. Nasdaq gives until June 22, 2026 to submit a compliance plan; trading remains on Nasdaq under “GWAV.”

Original reporting
Published May 27, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Greenwave Announces Receipt of Additional Delinquency Notice from Nasdaq — source image
Decision brief

The 30-second read

$GWAVBearishHigh
01

Why it matters

This adds another formal compliance strike and increases the probability of delisting unless the company executes on late filings and submits an acceptable regain-compliance plan by June 22, 2026.

02

Market read

Traders should focus on filing execution (late 10-Q/10-K) and Nasdaq’s acceptance of the compliance plan, as these are the primary catalysts for risk repricing.

03

What to watch

The release says there is no immediate effect on listing/trading; price may already reflect delinquency risk, so incremental impact depends on whether filings are imminent versus still delayed.

Relevance 9/10Timing: High: compliance plan deadline is June 22, 2026; additional risk persists until late 10-Q/10-K are filed and Nasdaq accepts the plan.

Background

Nasdaq issued an initial delinquency notice on April 22, 2026 for late 10-K; the company now reports a second notice tied to late Q1 10-Q, both under Rule 5250(c)(1).

Company-level read

Ticker impact

$GWAVBearishHigh confidence
Context

Greenwave received an additional Nasdaq delinquency notice for delayed Q1 10-Q filing, increasing delisting risk under Rule 5250(c)(1).

Expected impact

Near-term downside bias and elevated volatility as traders price worsening listing-risk; relief possible if late 10-Q/10-K filings land and Nasdaq accepts the plan.

Evidence & confidence

The notice explicitly states noncompliance due to delayed periodic filings and notes it could serve as an additional basis for delisting; the company also highlights no immediate trading halt but increased risk.

Market effects

Small-cap recycling/industrial services issuers with filing delays may see sector-wide multiple compression if investors generalize listing-risk.

Limited direct regional effect; impact is primarily on the issuer’s Nasdaq listing status rather than local fundamentals.

Low: this is a US exchange compliance event with limited cross-border fundamental linkage.

Counterpoint

If Greenwave quickly files the late 10-Q/10-K and Nasdaq accepts the compliance plan, the delisting overhang can fade faster than the market expects.

Key entities

  • Greenwave Technology Solutions, Inc.

    Nasdaq-listed metal recycler facing additional delinquency notice for delayed periodic SEC filings.

  • Nasdaq Stock Market LLC

    Listing authority issuing delinquency notices and evaluating compliance plans under Rule 5250(c)(1).

Related articles

$PVLAMedAI 8/10

Palvella Therapeutics Gets Priority Review for QTORIN Rapamycin NDA

Palvella Therapeutics (PVLA) received FDA acceptance and Priority Review for its QTORIN rapamycin NDA, targeting a February 28, 2027 decision. The NDA seeks approval to treat microcystic lymphatic malformations, a condition with no current FDA-approved therapies. Phase 3 SELVA results showed statistical significance across all efficacy endpoints. Palvella plans a potential U.S. launch in early 2027 if approved.

$PVLAMedAI 8/10

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

PALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Other Events. Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an esti

$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.